150 New Jobs for Sligo as Phibro announce major expansion into EU – McLoughlin

Fine Gael TD for Sligo – Leitrim and Assistant Government Whip, Tony McLoughlin, has announced that 150 new jobs are to be created in Sligo by Phibro Animal Health Corporation (PAHC).

The company is a diversified animal health and nutrition company which employs over 1,400 people globally with a direct presence in 33 countries.

The company will be located at the facility vacated by Eli Lilly – Elanco in 2016 in Finisklin. This will see the company employ 150 people over five years.

Speaking at the launch, Deputy McLoughlin said: “It really has been a fantastic few weeks for Sligo with major jobs announcements from Abtran, E3 Retail, and Live Tiles, showing how the county is benefiting from both indigenous and FDI investment.

“Since January almost 700 jobs have been created in Sligo.

“These announcements show the success of the Government’s commitment under the Regional Action Plans for Jobs to provide quality jobs in regional locations such as Sligo and I fully expect this positive trend to continue as Sligo has been prioritised for growth and development in the Government’s Ireland 2040 Plan.”

Phibro develops, manufactures, and markets products for a range of livestock including poultry, swine, and cattle. The company’s animal health range includes both small molecule and biologic products.

The 39,400 sq ft facility will be located on a 4.4 acre site at Finisklin Industrial Estate. It will consist of multiple clean rooms / contained sterile process areas with a central bio-service area and has the capability to support a range of biotechnology processes and the company has purchased the facility.

When fully operational, Phibro Sligo will produce live attenuated viral vaccines in a highly potent tablet form initially for the poultry market, with other areas to follow.

These are developed using a unique technology that enables the vaccines to be administered orally. The vaccines treat Newcastle disease, infectious Bronchitis and infectious Bursal disease.

The Sligo plant will be revalidated and recommissioned into approved use to the standards of regulatory authorities including the HPRA, EPA and Department of Agriculture, Food and the Marine.

ENDS